AzTrials
AzTrials

HIV InfectionsNCT00951249

Feasibility Study of a Multi-Component Intervention for Black Men Who Have Sex With Men

A study testing Referral of Partners, Screening for STIs and counseling and Peer health care system navigators in people with HIV Infections, run by HIV Prevention Trials Network at 8 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

It has been estimated that black men who have sex with men (MSM) account for one quarter of all new HIV infections in the US annually, yet little prevention work has been directed towards this population. Read more about this study

Who is it for?
Ages 18 years and older, men onlyHealthy volunteers can take part
Conditions the study is for
HIV Infections
What is being tested?
Referral of Partners, Screening for STIs and counseling and Peer health care system navigators
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,553 participants
Where
8 sitesUnited States
Study dates
Jul 2009to Dec 2011
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Willing and able to provide informed consent
  • Black, African American, Caribbean Black, or multiethnic Black
  • At least one instance of unprotected anal intercourse (UAI) with a man in the past six months
  • Residing in the metropolitan area and do not plan to move away during the time of study participation

Who cannot join

  • Co-enrollment in any other HIV interventional research study or have been enrolled in an HIV vaccine trial in which they were either in the active arm or do not know the arm in which they were enrolled.
  • Would be enrolled as a community-recruited participant in a category that has already reached its enrollment cap
  • Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Trial locations and contacts

8 sites in 1 country.

8 sites in 1 country

United States8 sites
  • The Ponce de Leon Ctr. CRS

    Atlanta, Georgia, 30308

  • The Fenway Institute

    Boston, Massachusetts, 02115

  • Hope Clinic of the Emory Vaccine Center CRS

    Decatur, Georgia, 30030

  • UCLA Vine Street CRS

    Los Angeles, California, 90038

  • NY Blood Ctr./Union Square CRS

    New York, New York, 10003

  • Harlem Hospital Center/Columbia University CRS

    New York, New York, 10032

  • San Francisco Vaccine and Prevention CRS

    San Francisco, California, 94102

  • George Washington University

    Washington D.C., District of Columbia, 20037

Other trials in United States

About this study

Official title: Feasibility Study of a Community-Level, Multi-Component Intervention for Black Men Who Have Sex With Men

It has been estimated that black men who have sex with men (MSM) account for one quarter of all new HIV infections in the US annually, yet little prevention work has been directed towards this population. The purpose of this study is to research and potentially design a new and better way to try and slow the spread of HIV among black MSM.

Read the detailed description

In the US, men who have sex with men (MSM) comprise the largest proportion of new HIV infections, with black MSM being infected at significantly higher rates. Differences in sexual-risk behaviors and substance use do not explain the disproportionate HIV rates by race among MSM. The most likely explanations are low frequency of HIV testing, high HIV prevalence within sexual networks, high prevalence of other sexual transmitted infections (STIs), and barriers to health care access and HIV/STI treatment. These result in later diagnoses of HIV-infected men, more frequent STIs, and fewer HIV-infected men having access to care.

The purpose of this study is to gather information on the achievability and acceptability of the following interventions:

A.) Referral of up to five sexual partners by index participants for enrollment into the study B.) Counseling and testing for HIV C.) Counseling and testing for other STIs D.) Counseling and referral for care offered to participants for issues such as substance use and mental health.

E.) Engagement with peer health care system navigators (PHNs) to facilitate uptake of health care and other services.

These interventions are designed to impact several factors related to the HIV epidemic among black MSM. At the individual level, the interventions will address personal risk factors for either acquiring or transmitting HIV, including identifying undiagnosed HIV or STI infections, and helping participants to reduce risk-behaviors, such as those influenced by drugs and alcohol. The interventions are also designed to have an impact at the population level. If successful, they will lower the viral load in HIV-infected men by identifying those who qualify for HIV treatment and intervening to increase treatment and access to healthcare. Overall, the study investigators propose that by lowering both the proportion of men with undiagnosed HIV infection and those with chronic, untreated infection, the rates of HIV transmission will be reduced among the black MSM population. This is a feasibility study, designed to provide estimates about the potential effectiveness of these interventions. These estimates will then be used to determine whether a large-scale trial of the interventions would be successful.

Approximately 2418 total participants will be enrolled into the study at six different sites. Participants will be enrolled in one of two ways: either directly from the community, or referred by other participants (sexual network partners). The total duration of the study will be two years. This includes 12 months for participant accrual and 12 months of follow-up for each participant. All participants will have an enrollment visit, during which he will complete a questionnaire covering topics such as sexual risk behaviors, drug and/or alcohol use, current and prior engagement with the health care system, barriers to HIV care, unmet service needs, frequented venues, attitudes about race, sexual history, research, and health care. Participants will also be asked to enumerate 5 social and 10 sexual network members (age, race, HIV status), information which will be used to better understand the characteristics of black MSM social and sexual networks.

Participants will be offered HIV and STI testing and counseling. Those with reactive HIV rapid test results will have HIV infection confirmed by Western blot and will have a CD4 cell count and viral load test performed. Counselors will provide post-test HIV participants counseling to those who have had HIV rapid test performed and will schedule all participants to return to the clinic approximately two weeks later to receive additional test results. The counselor will also discuss the participant's engagement in health care, and will determine the participant's health and other service needs. The counselor will also inquire about homophobic or partner violence and provide any care referrals if needed. Additionally, risk reduction counseling will be provided.

Study participation will end after the initial visit for three groups of participants. These groups include those who have: A.) an HIV-positive diagnosis prior to screening for this study and are either in care (have seen a health care provider for HIV-related care in the last six months)or who have unprotected sex only with HIV-infected partners. B.) HIV-uninfected participants enrolled after the site's 200 person cap for this category, and C.) participants who refuse HIV testing after the site's fist 20 participants in this category have been enrolled. Participants who fall into the categories listed above will provide only baseline cross-sectional data.

All other participants will then have the counselor explain about peer health care system navigation and introduce the participant to the PHN. The PHN will meet with the participant and schedule an initial discussion, unless the participant does not have any need for the navigation, in which case the PHN will plan to call after a few weeks to check for any emerging needs. The PHN will interact with the participant on a schedule that is independent of the study visit schedule and is determined by the participant's needs. The PHN's role will be to help the participant overcome his barriers to health care through a number of activities.

Follow-up visits are scheduled infrequently, so participants may be contacted periodically between visits to stay in touch and provide updated locator information. Visits will include the completion of a questionnaire, HIV testing for those who were not infected at the prior visit, with confirmation and follow-up tests if necessary. A viral load test will be performed for HIV-infected participants at the time of diagnosis and again at 52 weeks. All participants will receive STI counseling and testing at 26 and 52 weeks. Participants will receive counseling to include risk reduction counseling and pre- and post- test counseling, as needed. Participants will also be counseled for issues such as mental health and substance use and referred for care as appropriate. Participants will be asked to report any STI or HIV diagnoses they receive between visits and to provide documentation of diagnoses. Plasma specimens for testing will also be collected from all participants at all visits.

In order to collect additional information on the black MSM population, interviews and focus groups will also be a component in this study. Focus group meetings will be approximately 1.5 to 2 hours long and will be conducted at locations that allow for privacy and confidentiality. Interviews will last for between 60 to 90 minutes and will be conducted with individual participants. Interviews will be audio recorded and transcribed.

Conditions
HIV Infections
Being tested
Referral of Partners, Screening for STIs and counseling, Peer health care system navigators, Enhanced counseling
Keywords
MSM, HIV infections, HIV Seronegativity
Medical subject headings
HIV Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Referral of PartnersBehavioural

    Referral of up to five sexual partners by index participants for enrollment into the study

  • Screening for STIs and counselingBehavioural

    Identification of STIs and treatment or referral for treatment, if applicable

  • Peer health care system navigatorsBehavioural

    HIV/STI treatment and other medical and social services

  • Enhanced counselingBehavioural

    Counseling and referral for care offered to participants for issues such as substance use and mental health

Study groups in NCT00951249
Study groupRoleWhat they receive
AExperimentalHIV-infected and uninfected black MSM
Receives: Behavioral: Referral of Partners; Behavioral: Screening for STIs and counseling; Behavioral: Peer health care system navigators; Behavioral: Enhanced counseling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants enrolled at each city

    Measured: At 52 Weeks

  2. Proportion of participants who agree to HIV testing

    Measured: Throughout study

  3. Proportion of participants who agree to STI testing

    Measured: Throughout study

  4. Proportion of participants who use PHN

    Measured: Throughout study

  5. Proportion of participants who are newly diagnosed with HIV at enrollment

    Measured: At Study Entry

  6. Increase in condom use

    Measured: Study Entry to Week 52

  7. Decrease in viral load among HIV-infected participants who initiate HAART during their study participation

    Measured: At Week 52

  8. Decrease in STI

    Measured: At Study Entry to Week 52

Secondary outcomes (11)
  1. Number of participants with recent HIV infection

    Measured: At Study Entry

  2. Number of participants with acute HIV infection

    Measured: At Week 52

  3. Number of seroconversions during follow-up among those who are HIV-uninfected

    Measured: At Follow-up

  4. Number of sex partners

    Measured: At Study Entry, and Weeks 26 and 52

  5. Number of sero-discordant or sero-unknown partners

    Measured: At Study Entry, and Weeks 26 and 52

  6. Type and frequency of anal intercourse

    Measured: At Study Entry, and Weeks 26 and 52

  7. Level of condom use

    Measured: At Study Entry, and Weeks 26 and 52

  8. Partner change rate

    Measured: At Study Entry, and Weeks 26 and 52

  9. As individually self-reported by participants: network size, composition, density, multiplexity, durability, and homogeneity

    Measured: Throughout study

  10. Overlap of participant's sexual network with his social network

    Measured: Throughout study

  11. Attitudes of black MSM toward other prevention interventions

    Measured: Throughout study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Aug 2009 (estimated)
  2. Study startJul 2009
  3. Primary completionDec 2011
  4. Study completionDec 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
1,553 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00951249
Sponsor's protocol ID
HPTN 061
Other IDs
1U01AI068619
Status last verified
Aug 2022
First submitted
31 Jul 2009
Last updated
26 Aug 2022
Results posted
No

Publications

  • Bissessor M, Fairley CK, De Guingand D, Bradshaw CS, Chen MY. Delay in the diagnosis of early syphilis among men who have sex with men: need for greater community and health provider education. Int J STD AIDS. 2009 Jan;20(1):52-3. doi: 10.1258/ijsa.2008.008254.

    PubMed 19103894
  • Rowniak S. Safe sex fatigue, treatment optimism, and serosorting: new challenges to HIV prevention among men who have sex with men. J Assoc Nurses AIDS Care. 2009 Jan-Feb;20(1):31-8. doi: 10.1016/j.jana.2008.09.006.

    PubMed 19118769

Questions about this trial

What is this clinical trial studying?

A study testing Referral of Partners, Screening for STIs and counseling and Peer health care system navigators in people with HIV Infections, run by HIV Prevention Trials Network at 8 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants enrolled at each city (time frame: At 52 Weeks). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00951249, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT00951249 | AzTrials